Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non-exposed study
- PMID: 12488296
- DOI: 10.1093/annonc/mdg003
Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non-exposed study
Abstract
Background: To study the results of interval debulking surgery (IDS) in patients treated for 'unresectable' advanced stage ovarian cancer compared with primary debulking surgery (PDS) followed by chemotherapy.
Patients and methods: An exposed-non-exposed study including a group of 34 patients who underwent an IDS and were matched to an historic control group of 34 patients treated with PDS.
Results: Optimal cytoreductive surgery was achieved in 94% (32 out of 34) of patients in both groups. The rates of post-operative morbidity, blood transfusion and median length of hospitalisation were significantly reduced in the study (IDS) group, but survival did not differ in both groups.
Conclusions: IDS in patients with advanced stage ovarian cancer offers the same chance of survival as PDS, but it is better tolerated.
Similar articles
-
Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer.Gynecol Oncol. 2014 Nov;135(2):223-30. doi: 10.1016/j.ygyno.2014.09.002. Epub 2014 Sep 16. Gynecol Oncol. 2014. PMID: 25220627
-
Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.J Clin Oncol. 2008 Jan 1;26(1):83-9. doi: 10.1200/JCO.2007.13.1953. Epub 2007 Nov 19. J Clin Oncol. 2008. PMID: 18025437
-
The INTERNATIONAL MISSION study: minimally invasive surgery in ovarian neoplasms after neoadjuvant chemotherapy.Int J Gynecol Cancer. 2019 Jan;29(1):5-9. doi: 10.1136/ijgc-2018-000012. Int J Gynecol Cancer. 2019. PMID: 30640676
-
Role of neoadjuvant chemotherapy in the management of advanced ovarian cancer.Asian Pac J Cancer Prev. 2015;16(6):2369-73. doi: 10.7314/apjcp.2015.16.6.2369. Asian Pac J Cancer Prev. 2015. PMID: 25824766
-
Interval debulking surgery in advanced epithelial ovarian cancer.Best Pract Res Clin Obstet Gynaecol. 2002 Aug;16(4):573-83. doi: 10.1053/beog.2002.0302. Best Pract Res Clin Obstet Gynaecol. 2002. PMID: 12413935 Review.
Cited by
-
The optimal time for surgery in women with serous ovarian cancer.Can J Surg. 2016 Aug;59(4):223-32. doi: 10.1503/cjs.014315. Can J Surg. 2016. PMID: 27240134 Free PMC article.
-
Development of multiplexed bead-based immunoassays for the detection of early stage ovarian cancer using a combination of serum biomarkers.PLoS One. 2012;7(9):e44960. doi: 10.1371/journal.pone.0044960. Epub 2012 Sep 10. PLoS One. 2012. PMID: 22970327 Free PMC article.
-
Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A survival study.Indian J Med Paediatr Oncol. 2015 Jan-Mar;36(1):38-42. doi: 10.4103/0971-5851.151781. Indian J Med Paediatr Oncol. 2015. PMID: 25810573 Free PMC article.
-
Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: a retrospective study of 574 patients.BMC Cancer. 2006 Jun 8;6:153. doi: 10.1186/1471-2407-6-153. BMC Cancer. 2006. PMID: 16759398 Free PMC article.
-
Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.J Ovarian Res. 2016 Dec 2;9(1):85. doi: 10.1186/s13048-016-0294-z. J Ovarian Res. 2016. PMID: 27912779 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous